17 March 2016 - PHARMAC is pleased to announce the approval of an agreement with BioMarin Pharmaceutical Australia Pty Ltd to list galsulfase (Naglazyme) for people with MPS VI in the Pharmaceutical Schedule.

No changes were made to the proposal following consultation. In summary, the effect of the decision is that galsulfase (Naglazyme) will be funded in the community under Special Authority criteria and in DHB hospitals subject to restrictions. Listing in the Pharmaceutical Schedule would occur subject to Medsafe approval of the pharmaceutical.

Galsulfase is the second medicine funded as a result of the Medicines for Rare Disorders Request for Proposals process.

For more details, go to: http://www.pharmac.govt.nz/news/notification-2016-03-17-galsulfase/